Ugrás a tartalomra
Merck
Összes fotó(1)

Fontos dokumentumok

MAB8257B

Sigma-Aldrich

Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated

clone A1, Chemicon®, from mouse

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez


About This Item

UNSPSC kód:
12352203
eCl@ss:
32160702
NACRES:
NA.41
klón:
A1, monoclonal
application:
IF
faj reaktivitás:
human
technika/technikák:
immunofluorescence: suitable
citations:
18

biológiai forrás

mouse

Minőségi szint

konjugátum

biotin conjugate

antitest forma

purified immunoglobulin

antitest terméktípus

primary antibodies

klón

A1, monoclonal

faj reaktivitás

human

gyártó/kereskedő neve

Chemicon®

technika/technikák

immunofluorescence: suitable

izotípus

IgG2a

kiszállítva

wet ice

Egyediség

Specific for the Influenza A nucleoprotein. Has stronger binding with N1-type Flu A. Has been shown to react with the H5N1 strain. No cross reactivity seen to influenza B or other respiratory viruses.

Immunogén

Epitope: nucleoprotein
Influenza A

Alkalmazás

Detect Influenza A using this Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated validated for use in IF.
Immunofluorescence

Optimal dilutions must be determined by end user.
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral

Fizikai forma

Biotin conjugated purified immunoglobulin. Liquid in 0.01M PBS, pH=7.1, 0.1% Sodium Azide with 15 mg/mL BSA as stabilizer.

Tárolás és stabilitás

Maintain at 2 to 8°C for up to 12 months from date of receipt. Protect from Light.

Egyéb megjegyzések

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Jogi információk

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Jogi nyilatkozat

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Nem találja a megfelelő terméket?  

Próbálja ki a Termékválasztó eszköz. eszközt

Tárolási osztály kódja

12 - Non Combustible Liquids

WGK

WGK 2

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable


Analitikai tanúsítványok (COA)

Analitikai tanúsítványok (COA) keresése a termék sarzs-/tételszámának megadásával. A sarzs- és tételszámok a termék címkéjén találhatók, a „Lot” vagy „Batch” szavak után.

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Roozbeh Abedini-Nassab et al.
Micromachines, 12(7) (2021-07-03)
Magnetic nanoparticles have attracted significant attention in various disciplines, including engineering and medicine. Microfluidic chips and lab-on-a-chip devices, with precise control over small volumes of fluids and tiny particles, are appropriate tools for the synthesis, manipulation, and evaluation of nanoparticles.
Felix Broecker et al.
NPJ vaccines, 4, 31-31 (2019-07-26)
Current seasonal influenza virus vaccines only provide limited, short-lived protection, and antigenic drift in the hemagglutinin surface glycoprotein necessitates their annual re-formulation and re-administration. To overcome these limitations, universal vaccine strategies that aim at eliciting broadly protective antibodies to conserved
Erin E H Tran et al.
mBio, 7(2), e00257-e00257 (2016-03-24)
Influenza viruses expressing chimeric hemagglutinins (HAs) are important tools in the quest for a universal vaccine. Using cryo-electron tomography, we have determined the structures of a chimeric HA variant that comprises an H1 stalk and an H5 globular head domain
Sergey Yegorov et al.
Cell reports. Medicine, 3(2), 100509-100509 (2022-03-05)
The induction of broadly neutralizing antibodies (bNAbs) that target the hemagglutinin stalk domain is a promising strategy for the development of "universal" influenza virus vaccines. bNAbs can be boosted in adults by sequential exposure to heterosubtypic viruses through natural infection
Mehfuz Zaman et al.
Clinical & translational immunology, 10(9), e1337-e1337 (2021-09-17)
The upper respiratory tract is the major entry site for Streptococcus pyogenes and influenza virus. Vaccine strategies that activate mucosal immunity could significantly reduce morbidity and mortality because of these pathogens. The severity of influenza is significantly greater if a

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással